Skip to content

PTC Therapeutics PTCT Total Cost of Revenue

Discontinued — last reported Q4 '19

Total Cost of Revenue at other companies

BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$195M+28.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$9.94M+277%
United Therapeutics logo
United TherapeuticsUTHR
$133.4M+44.2%
Biogen logo
BiogenBIIB
$661M+5.0%
ALN
Alnylam PharmaceuticalsALNY
LQD
Liquidia CorporationLQDA

Other financials

Income statement

See full
Revenue$272.6M-76.8%
Operating income$45.0M-95.4%
Net income-$2.8M-100%
EPS (diluted)-$0.03-100%

Balance sheet

See full
Cash & equivalents$834.0M-43.7%
Total debt$395.1M+0.1%
Total equity-$180.5M+2.9%
Total assets$2.9B+8.0%

Cash flow

See full
Operating cash flow-$59.0M-107%
CapEx$1.2M-30.6%
Free cash flow-$60.2M-107%

Valuation

See full
Market cap$6.55B+40.3%
Enterprise value$6.11B+77.3%
P/E
P/S7.9×+5.3×

Profitability

See full
Gross margin96%
Operating margin1.6%-38.7pp
Net margin42.3%+27.4pp
FCF margin39.1%+32.8pp

Returns & leverage

See full
Return on equity-216.7%
Debt / equity372.3×
Current ratio2.4×-1.5×

Where this comes from

Reported directly by PTC Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The official record: PTC Therapeutics’s 10-K, filed March 2, 2020, on SEC EDGAR. View the filing →

Questions, answered.

What does total cost of revenue mean?
The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.